Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle”In the company’s words, NCT04518137 on ClinicalTrials.gov
- Tested for
- Hepatocellular Carcinoma (2 trials), Advanced Solid Tumors, Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer and 1 more
- Main trialPhase 2
- “This is a single-arm and open-label study of ATG-008 for the Treatment of Patients With advanced Solid Tumors harboring NFE 2L2, STK11, RICTOR or other specific genetic alterationts”In the company’s words, NCT04518137 on ClinicalTrials.gov
- Other names
- ATG-008
Other drugs for Hepatocellular Carcinoma
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Terminated | 30 May 2022 | A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH) | |
| Phase 2Terminated | 3 Aug 2022 | Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects | |
| Phase 1/2Completed | 15 Nov 2016 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | |
| Phase 1Terminated | 12 Dec 2023 | Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026